Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 4/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 5/20 | 0.35 |
| ▸ | CD38 | P28907 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021286 | 0.89 | TYK2 (0.43) | STAT6HPGDTYK2AURKAPDPK1 | |
| SCHEMBL2696907 | 0.88 | JAK3 (0.46) | STAT6HPGDTYK2AURKAPDPK1 | |
| SCHEMBL2695045 | 0.86 | JAK3 (0.46) | STAT6HPGDTYK2AURKAPDPK1 | |
| SCHEMBL17021313 | 0.86 | ADORA2B (0.43) | STAT6AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL19010326 | 0.83 | TYK2 (0.42) | STAT6HPGDTYK2BDKRB1MEN1 | |
| SCHEMBL17021278 | 0.82 | MAPK10 (0.51) | STAT6TYK2SYKJAK2JAK1 | |
| SCHEMBL2693088 | 0.81 | STAT6 (0.53) | STAT6TYK2BDKRB1JAK2JAK1 | |
| SCHEMBL17021273 | 0.80 | TYK2 (0.45) | STAT6HPGDTYK2F10MEN1 | |
| SCHEMBL19010312 | 0.79 | ADORA2B (0.44) | STAT6TYK2 | |
| SCHEMBL17021291 | 0.78 | STAT6 (0.49) | STAT6TYK2SYKKMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885HPGD 1667/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.